ALK and cancer: Moreover, upstream of both RAF and PI3′-kinase signaling are the large family of receptor tyrosine kinases, such as EGFR, MET, ROS, ALK, and NTRK, that are mutated in a wide range of different cancers and for which there are numerous FDA-approved drugs linked to predictive biomarkers.